Biogen/Idec: still a matter of size

Biogen/Idec: still a matter of size
The merger of Biogen and Idec Pharmaceuticals, announced June 23, is likely to help the two relatively isolated companies increase presence in their disease areas. The annual R&D budget for the new pharmaceutical entity, to be called Biogen Idec Inc, will be $500 million, according to company reports.

Click here for reuse options!
Copyright 2003 Biotechblog

Leave a Reply

%d bloggers like this: